Welcome to our dedicated page for Quantum-Si news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si stock.
Quantum-Si Incorporated develops proteomics technology for single-molecule protein sequencing and protein analysis. Its updates center on benchtop platform development, real-time kinetic-based detection, and product work around Proteus instruments, the KinetIQ Array and Platinum Pro customer use.
Recurring company news includes quarterly financial results and non-GAAP operating measures, Proteus prototype and integrated-instrument sequencing milestones, amino-acid detection coverage, customer sample testing, scientific posters and manuscripts using Quantum-Si technology, investor conference participation, and equity-inducement grants under Nasdaq rules.
Quantum-Si (Nasdaq: QSI) announced a new manuscript (pre-print, April 14, 2026) showing single-molecule protein sequencing helped identify hybrid human–yeast cohesin complexes relevant to cancer biology. The study used QSI technology to directly demonstrate physical assembly of human and yeast cohesins, a finding that could inform therapeutic discovery.
Quantum-Si (Nasdaq: QSI) granted 61,439 restricted stock units (RSUs) as inducement awards to new employees under its 2023 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on June 20, 2027, with the remainder vesting in 12 equal quarterly installments, subject to continued employment and plan terms.
Quantum-Si (Nasdaq: QSI) completed sequencing of multiple customer samples on a Proteus prototype, testing samples on both Platinum Pro and the Proteus prototype.
According to the company, the Proteus prototype with a developmental sequencing kit delivered improved amino acid coverage, longer read lengths, more peptides identified and greater sequencing output versus Platinum Pro.
Quantum-Si (NASDAQ: QSI) announced a multi-city roadshow to build awareness for its Proteus protein sequencing platform and develop a customer funnel ahead of commercial launch.
First events are in Seattle on April 7, 2026, Washington, D.C. on April 30, 2026, and Houston on May 5, 2026; additional U.S. and European dates will follow.
Quantum-Si (Nasdaq: QSI) granted 88,781 restricted stock units (RSUs) to new employees under its 2023 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest 25% on March 20, 2027, with the remainder vesting in 12 equal quarterly installments, subject to continued employment and plan terms.
Quantum-Si (Nasdaq: QSI) reported fourth quarter 2025 revenue of $0.5M and full-year 2025 revenue of $2.4M, with gross margins of 27% (Q4) and 47% (full year).
The company announced a Proteus list price of $425,000, reiterated a year-end 2026 launch target, and provided 2026 guidance: revenue ~$1.0M, adjusted operating expenses ≤$98.0M, and total cash usage ≤$93.0M. Cash and investments totaled $215.8M as of December 31, 2025.
Quantum-Si (Nasdaq: QSI) announced that its Compensation Committee granted 52,296 restricted stock units (RSUs) to new employees under the company’s 2023 Inducement Equity Incentive Plan.
The RSUs vest 25% on March 20, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment and plan terms.
Quantum-Si (Nasdaq: QSI) will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026. Management will host a conference call and live webcast at 4:30 PM ET the same day to discuss results and provide a business update.
Webcast access and dial-in registration details are available on the company’s Investors section; an archived replay will be posted after the event.
Quantum-Si (NASDAQ: QSI) announced two new manuscripts showing single-molecule protein sequencing applied to clinical proteomics and pathogen/toxin detection. One paper on hemoglobin variants was peer reviewed and published in Journal of Analytical Chemistry; a U.S. Naval Research Laboratory preprint reports a workflow delivering biological sample-to-result in under 24 hours.
The studies demonstrate direct identification of difficult hemoglobin variants, detection of long single-domain antibodies and toxoids from complex matrices, and highlight the company’s benchtop Proteus strategy.
Quantum-Si (Nasdaq: QSI) launched a Version 3 Library Preparation Kit and a suite of data analysis enhancements on December 22, 2025. The Version 3 kit requires 200 ng or less total protein input, a 100-fold improvement versus the prior kit, and internal validation shows detection of proteins with as little as 1–2 ng input (under 1% relative abundance in mixtures). The analysis updates add detection of methionine, improve peptide alignment and protein inference, and expand amino acid coverage to 15 amino acids. Combined with the Version 4 Sequencing Kit launched September 2025, the company says users should see improved analysis of scarce samples and low‑abundance biomarkers.